Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „elapse“
Suchtreffer
Begriffe & Kennungen
Columvi · 4.8 · Adverse reactions occurring in relapsed or refractory DLBCL patients treated with Columvi monotherapy (n=145)
Eintrag öffnenColumvi · 4.8 · Table 6. Adverse reactions reported in patients with relapsed or refractory DLBCL treated with Columvi monothe
Eintrag öffnenFarydak · 4.8 · Infections Relapsed or refractory multiple myeloma patients are at risk of infections. Potential contributing
Eintrag öffnenHycamtin · 4.8 · In clinical studies involving patients with relapsed small cell lung cancer, the dose-limiting toxicity of ora
Eintrag öffnenHycamtin · 4.8 · In dose-finding studies involving 523 patients with relapsed ovarian cancer and 631 patients with relapsed sma
Eintrag öffnenHycamtin · 4.8 · Safety data are presented based on an integrated data set of 682 patients with relapsed lung cancer administer
Eintrag öffnenItuxredi · 4.8 · IgG levels In the clinical trial evaluating rituximab maintenance treatment in relapsed/refractory follicular
Eintrag öffnenLenvima · 4.8 · In patients with relapsed/refractory osteosarcoma, pneumothorax was reported at a frequency higher than that o
Eintrag öffnenLynozyfic · 4.8 · The safety population described includes 117 patients with relapsed or refractory multiple myeloma who receive
Eintrag öffnenLynparza · 4.8 · In patients with BRCAm platinum-sensitive relapsed ovarian cancer who had received at least two prior lines of
Eintrag öffnenMabThera · 4.8 · 92 3 or 4 cardiac disorders was low both in the first-line study (4% R-FC, 3% FC) and in the relapsed/refracto
Eintrag öffnenMabThera · 4.8 · IgG levels In the clinical trial evaluating MabThera maintenance treatment in relapsed/refractory follicular l
Eintrag öffnenMabThera · 4.8 · IgG levels In the clinical trial evaluating MabThera maintenance treatment in relapsed/refractory follicular l
Eintrag öffnenMabThera · 4.8 · IgG levels In the clinical trial evaluating MabThera maintenance treatment in relapsed/refractory follicular l
Eintrag öffnenMinjuvi · 4.8 · 9 Table 3: Adverse reactions in patients with relapsed or refractory FL who received tafasitamab in combinatio
Eintrag öffnenMinjuvi · 4.8 · Patients with relapsed or refractory FL after at least one line of systemic therapy The safety of tafasitamab
Eintrag öffnenMinjuvi · 4.8 · Summary of the safety profile Patients with relapsed or refractory DLBCL The safety of tafasitamab in patients
Eintrag öffnenMinjuvi · 4.8 · Table 2: Adverse reactions in patients with relapsed or refractory DLBCL who received tafasitamab in combinati
Eintrag öffnenPolivy · 4.8 · 12 a ADR associated with fatal outcome b ADRs observed in relapsed or refractory DLBCL only. c ADRs observed i
Eintrag öffnenPotactasol · 4.8 · In dose-finding studies involving 523 patients with relapsed ovarian cancer and 631 patients with relapsed sma
Eintrag öffnen